First, most patients in our meta-analysis were in stage IIIB or IV of NSCLC [14–16,19,21–24] and only one study with stage II-III NSCLC[20], so we could not evaluate the efficacy of COX-2 inhibitors for early NSCLC. The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.